Compass therapeutics announces publication in the journal science of preclinical data supporting the potential of ctx-2026, a novel antibody to the butyrophilin btn3a1, in ovarian cancer tumor models

The journal science has published preclinical data supporting ctx-2026, compass therapeutics inc.’s novel anti-cd277 antibody product candidate

CODI Ratings Summary

CODI Quant Ranking